GILEAD SCIENCES (NASDAQ: GILD) Breakout Swing Trading Idea
Last update: Aug 16, 2022
TRADING IDEA (Momentum Swing Trading Breakout)
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read the full profile here.
STRATEGY
Breakout Swing Trading Idea
- clean breakout during last trading session, wide range bullish bar closed near the high of day (+5.2%)
- strongly increased buying volume
- closing price above current daily resistance level
- long term trend (weekly chart), price breakout above sideways trading channel
Last earnings: 2022-08-02
Next earnings: 2022-10-26
ACTUAL SETUP
- Buy Stop | $66.36
- Limit | $66.50
- Stoploss | $63.44
- Target | first and second target area on weekly chart
ADDITIONAL INFO/TIPS
- Use our ChartMill Postion Sizing Tool to calculate the maximum number of shares you can buy, depending on your available capital!
- Why using Stop Limit Orders?
Disclaimer: These trading ideas are merely to demonstrate what ChartMill is capable of and shows some typical results of a breakout filter. It is in no way actual financial advise to invest or trade in these stocks. The author has no pre-existing position in any of these stocks.
GILEAD SCIENCES INC
NASDAQ:GILD (5/17/2024, 7:01:44 PM)
After market: 67.58 -0.14 (-0.21%)67.72
-0.14 (-0.21%)
GILD News
2 hours ago - PRLogThe P3 App: Empowering and Elevating Underprivileged Youth from Socioeconomically Disadvantaged Areas Through Innovative MentorshipCHICAGO - May 18, 2024 - PRLog -- The Pulse of Perseverance alongside Gilead is proud to announce the launch of the P3 mobile app, a pioneering platform unveiled at our signature benefit event on May 16, now available on the app store. Designed to transform the landscape of mentorship, the P3 app connects students from underprivileged backgrounds with mentors in underrepresented fields, fostering a supportive community and opening doors to internships and career opportunities.Amidst the backdrop of systemic barriers that often hinder the academic and professional aspirations of Black children, the P3 app stands as a beacon of hope and opportunity. It not only bridges the gap in resource access but also challenges the status quo by providing a direct funnel to success in advanced fields where youth from socioeconomically disadvantaged areas are vastly underrepresented.Features of the P3 App:
5 hours ago - Gilead Sciences, Inc.Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
2 days ago - InvestorPlacePenny Stock Sleepers: 7 Under-the-Radar Gems Ready to LaunchPenny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns.
3 days ago - Market News VideoSee Which Of The Latest 13F Filers Holds Gilead Sciences
4 days ago - Gilead Sciences, Inc.Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell TherapyS&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
9 days ago - Gilead Sciences, Inc.Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
9 days ago - InvestorPlaceBiotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing MedicineThese biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.
9 days ago - ChartmillWhy NASDAQ:GILD qualifies as a good dividend investing stock.Why GILEAD SCIENCES INC (NASDAQ:GILD) is a Top Pick for Dividend Investors.
10 days ago - Market News VideoNoteworthy Wednesday Option Activity: GILD, BKNG, TGNA
11 days ago - Gilead Sciences, Inc.Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
12 days ago - InvestorPlaceBargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce BackIf you want your shot at significant upside, speculate on these stocks near 52-week lows that can prove the critics wrong.
